Positron Emission Tomography and Magnetic Resonance Imaging in the Study of Cognitively Normal Persons at Differential Genetic Risk for Alzheimer’s Dementia

eric m reiman,richard j caselli,kewei chen,g alexander
DOI: https://doi.org/10.1007/978-3-642-59300-0_12
2004-01-01
Abstract:Patients with Alzheimer's dementia (AD) have characteristic and progressive reductions in fluorodeoxyglucose positron emission tomography (PET) measurements of the cerebral metabolic rate for glucose and in magnetic resonance imaging (MRI) measurements of hippocampal and whole brain volume. We have been using PET and MRI to characterize and compare PET and MRI measurements in cognitively normal persons with two copies, one copy, and no copies of the apolipoprotein E epsilon4 allele, a common AD susceptibility gene. This article reviews and updates our previously published PET and MRI findings. It indicates how these imaging techniques could be used to help bridge existing gaps between ante-mortem and post-mortem studies of AD, non-demented persons at risk for AD, and relevant animal models. It suggests how they could provide clues about the earnest brain changes involved in the pathogenesis of AD and assist in the identification of new targets for the discovery of drugs in the treatment and prevention of this disorder. Finally, it describes a brain imaging strategy for the efficient evaluation of prevention therapies, without having to conduct studies in thousands of research subjects, restrict these studies to those who are older or are already symptomatic, or wait many years to determine whether or when treated individuals develop mild cognitive impairment or AD.
What problem does this paper attempt to address?